ArticleaBIOTECH2024
Developing a CRISPR/FrCas9 system for core promoter editing in rice.
Article in aBIOTECH, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Genome Editing Approaches in Flax (International journal of molecular sciences · 2026Review
- Engineering non-coding DNA Elements in Rice: an Elegant Approach To fine-tune Agronomical Advantageous Traits.Rice (New York, N.Y.) · 2025Review
- Advancements in genomic crop techniques and considerations for regulation and food safety.Transgenic research · 2025Review
- CRISPR-Cas applications in agriculture and plant research.Nature reviews. Molecular cell biology · 2025Review
- Conditional knockdown of gene expression in plants via 3' UTR editing.Plant communications · 2025Article
- Construction and Validation of CRISPR/Cas Vectors for Editing theCurrent issues in molecular biology · 2024Article
- Rice Promoter Editing: An Efficient Genetic Improvement Strategy.Rice (New York, N.Y.) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small mutations in the core promoter region of a gene may result in substantial changes in expression strengths. However, targeting TA-rich sequences of core promoters may pose a challenge for Cas9 variants such as SpCas9 and other G-rich PAM-compatible Cas9s. In this study, we engineered a unique FrCas9 system derived from Supplementary Information: The online version contains supplementary material available at 10.1007/s42994-024-00157-5.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.